Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia
Authors:
- 1 December 2017
- journal article
- research article
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 174 (12) , 1195-1202
Abstract
Objective:The authors assessed the efficacy, safety, and tolerability of MIN-101, a compound with affinities for sigma-2 and 5-HT2A receptors and no direct dopamine affinities, in comparison with placebo in treating negative symptoms in stabilized patients with schizophrenia.Method:The trial enrolled 244 patients who had been symptomatically stable for at least 3 months and had scores of at least 20 on the negative subscale of the Positive and Negative Syndrome Scale (PANSS). After at least 5 days’ withdrawal from all antipsychotic medication, patients were randomly assigned to receive placebo or 32 mg/day or 64 mg/day of MIN-101 for 12 weeks. The primary outcome measure was the PANSS negative factor score (pentagonal structure model). Secondary outcome measures were PANSS total score and scores on the Clinical Global Impressions Scale (CGI), the Brief Negative Symptom Scale, the Brief Assessment of Cognition in Schizophrenia, and the Calgary Depression Scale for Schizophrenia.Results:A statistically sign...Keywords
This publication has 39 references indexed in Scilit:
- Monotherapy treatment with cariprazine for the treatment of predominant negative symptoms of patients with schizophrenia: A double-blind, active comparator-controlled trialEuropean Psychiatry, 2016
- Restrictive symptomatic inclusion criteria create barriers to clinical research in schizophrenia negative symptoms: An analysis of the CATIE datasetEuropean Neuropsychopharmacology, 2014
- Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of SchizophreniaJAMA Psychiatry, 2014
- Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatmentEuropean Neuropsychopharmacology, 2014
- Negative symptoms, past and present: A historical perspective and moving to DSM-5European Neuropsychopharmacology, 2014
- A selective sigma‐2 receptor ligand antagonizes cocaine‐induced hyperlocomotion in miceSynapse, 2013
- Placebo response trajectories in short-term and long-term antipsychotic trials in schizophreniaSchizophrenia Research, 2011
- The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive batterySchizophrenia Research, 2004
- Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophreniaEuropean Archives of Psychiatry and Clinical Neuroscience, 2001
- Validation of the 16-item negative symptom assessmentJournal of Psychiatric Research, 1993